Andere talen Percheron Therapeutics Limited

Aandelen

PER

AU0000317281

slotkoers Australian S.E. Andere beurzen 00:00:00 03-07-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,084 ^AUD	+5,00%		+2,44%	+42,37%

29/05	Percheron Therapeutics rondt inschrijving af voor fase 2-studie naar spierdystrofie; aandelen stijgen 3%	MT
28/02	Percheron Therapeutics Limited rapporteert resultaten voor het halfjaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Percheron Therapeutics Appoints CFO	17/06
Percheron Therapeutics Names Chief Medical Advisor	03/06
Percheron Therapeutics Completes Enrollment for Phase Two Muscular Dystrophy Trial; Shares Rise 3%	29/05
Percheron Therapeutics Secures US Patent for Muscular Dystrophy Medicinal Candidate	20/05
WHO Selects International Nonproprietary Name for Percheron Therapeutics' Drug Candidate ATL1102	06/05
Percheron Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	28/02
Dimerix Appoints Nonexecutive Chair	20/11
Antisense Therapeutics Limited has Changed its Name to Percheron Therapeutics Limited	15/11
Antisense Therapeutics Launches Share Sale Facility for Unmarketable Parcels	09-10-23
Antisense Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	25-08-23
Antisense Therapeutics' Share Purchase Plan Raises AU$3.3 Million	21-08-23
Antisense Therapeutics Appoints CEO/Managing Director	07-08-23
Antisense Therapeutics Limited Announces Commencement of James Garner as Chief Executive Officer, Effective 7 August 2023	07-08-23
Antisense Therapeutics Limited Announces Management Changes	07-08-23
Antisense Therapeutics to Launch Share Purchase Plan; Shares Plunge 8%	20-07-23
Antisense Therapeutics Limited Receives MHRA Approval for ATL1102 Phase IIb DMD Clinical Trial in UK	27-06-23
Antisense Therapeutics Doses First Patient in Duchenne Muscular Dystrophy Drug Trial; Shares Jump 11%	08-06-23
Antisense Therapeutics Appoints CEO/Managing Director	08-05-23
Antisense Therapeutics Limited Announces the Appointment of James Garner as Chief Executive Officer, Effective 07 August 2023	08-05-23
Antisense Therapeutics Limited Appoints James Garner as Managing Director and to Join the Board as a Non-Executive Director	08-05-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Percheron Therapeutics Limited

Aandelen

PER

AU0000317281

Andere talen

Filters